このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

全身性エリテマトーデス患者の脳波記録

2026年11月3日 更新者:Bruce Volpe、Northwell Health

全身性エリテマトーデス患者の脳波記録に存在するシータ-ガンマ結合が認知機能障害の客観的マーカーとして機能するかどうかのテスト

Patients with systemic lupus erythematosus (SLE) often experience a frustrating decline of their cognitive skills that includes considerable problems in attention, learning, and memory. This lupus-related cognitive dysfunction (termed SLE-CD) is recognized as the most prevalent of the nineteen neuropsychiatric SLE syndromes, as it affects up to 80% of patients and can significantly decrease their quality of life. The goal is to have tools that can be used for diagnosis and for monitoring responses after targeted interventions and therapies. This study will focus on electroencephalographic (EEG) signals, which will be detected noninvasively from scalp placed surface electrodes while the subjects are in a state of wakeful rest. Our hypothesis is that a subset of brain oscillations known as theta and gamma, and their co-modulation or coupling will be disrupted in SLE patients. This research protocol will subject patients with systemic lupus erythematosus (SLE) to scalp electroencephalography (EEG), with the goal of determining whether specific EEG patterns ('theta-gamma coupling') appear abnormal during wakeful-rest periods of 20 minutes. The investigators are interested in using scalp EEG because it is a standard, safe and robust technique for monitoring the electrophysiological activity of neurons in the cerebral cortex.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Patients will sit comfortably in a quiet room in a wakeful state and perform simple operations with toy blocks and look at three dimensional objects and answer some questions. The EEG electrodes fit into a custom-made cap and will effectively transmit wave activity just by touching the skin surface of the scalp. There is no need for electrode paste so at the end of the experiment the patient can remove the cap and go home. The entire procedure including fitting of the EEG cap will take about an hour.

研究の種類

観察的

入学 (推定)

40

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • New York
      • Manhasset、New York、アメリカ、11030
        • 募集
        • Northwell Health-Feinstein Insitute
        • コンタクト:
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

サンプリング方法

確率サンプル

調査対象母集団

Twenty of the SLE subjects that have participated in prior brain imaging studies. The other 20 SLE subjects will be recruited from 2 ongoing observational studies of brain involvement in SLE.

説明

Inclusion Criteria:

  1. Must be able to understand and provide informed consent.
  2. Must be ≥18 and ≤65years of age.
  3. Must be female.
  4. Must fulfill the 1997 American College of Rheumatology (ACR) revised criteria for the diagnosis of SLE or the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Criteria for SLE.
  5. Must have stable disease activity and medication doses for 4 weeks prior to screening. Stable disease activity is defined as no increase in disease activity requiring an increase or change in medications.
  6. Must be on a corticosteroid dose that is ≤ prednisone 10 mg daily, or equivalent.
  7. Must have demonstrated significantly increased metabolism in the hippocampus, temporal or parietal lobes on prior fluoro-deoxy glucose (FDG)-PET imaging.

Exclusion Criteria:

  1. Inability or unwillingness to give written informed consent or comply with study protocol.
  2. History of neurological diseases including, but not limited to, severe head injury or history of brain surgery, stroke, seizure, toxic exposure, mental retardation, migraine headaches, multiple sclerosis, dementia.
  3. History of documented transient ischemic attacks within 6 months of screening.
  4. History of illicit drug or alcohol dependence/abuse within the past 12 months.
  5. Current use of antipsychotic, anticonvulsant, antidepressant (except for selective serotonin reuptake inhibitors) or anxiolytic medications (short acting anxiolytic medications are allowed if taken as needed with > 5 half-lives prior to assessments).
  6. History of chronic pain; current and/or chronic use of narcotic analgesia for > 21 days (total) within the last 3 months, or last dose less than 5 days prior to assessment.
  7. Increased disease activity within 4 weeks of screening defined by an increase in SLEDAI by 3 points or more, exclusive of points from serologies, which prompts an increase in or new addition of SLE medications.
  8. History of a diagnosis of a primary psychiatric disorder preceding SLE diagnosis.
  9. Current active acute infections requiring antibiotics within 2 weeks of screening and chronic known infections (eg. hepatitis B, C, and/or HIV).
  10. Co-existing other autoimmune disease(s) other than autoimmune thyroid disease and secondary Sjogren's Syndrome.
  11. The presence of uncontrolled, severe hypertension, diabetes or heart disease.
  12. Impaired renal function with an estimated glomerular filtration rate (eGFR)< 30.
  13. Presence of any active medical condition that in the opinion of the investigator may contribute to cognitive and/or behavioral disturbances.
  14. Use of investigational drugs within 30 days or 5 half-lives before the study visit, whichever is longer.
  15. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
  16. Current treatment with cyclophosphamide, addition of belimumab within 4 months, addition of any disease modifying drug or biologic within 3 months of screening, and/or rituxan within 6 months.
  17. Limited fluency with English or Spanish that in the opinion of the investigator would limit the subject's performance on the assessments.
  18. Pregnant and/or lactating women.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:CASE_CONTROL
  • 時間の展望:PROSPECTIVE

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
A measure of the amount and relationship of theta and gamma waves in the EEG recording. The ability to perform the block building task and the ability to choose among unfolded three-dimensional objects.
時間枠:Aim 1 will take the first 24 patients and they will spend an hour and a half undergoing EEG measuring TGC. For Aim 2 the patients will undergo EEG measuring TGC and predict the subsequent PET scan - which will occur under a separate protocol.

Patient will build with toy blocks and three dimensional combination will suffice. The patient will also observe three dimensional objects - cubes, for example, that are unfolded and choose a matching object from an array that includes the object and three foils. EEG activity will be recorded during this period.

As the subjects will be fitted with noninvasive EEG caps (using dry electrodes that will contact the scalp directly) which will record the ongoing brain activity while the subjects, in a wakeful resting mode attempt to build with the toy blocks and analyze the three dimensional figures. This activity will go on for approximately 20 minutes.

The EEG signals will be analyzed to determine the theta gamma coupling (TGC).

Aim 1 will take the first 24 patients and they will spend an hour and a half undergoing EEG measuring TGC. For Aim 2 the patients will undergo EEG measuring TGC and predict the subsequent PET scan - which will occur under a separate protocol.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年4月22日

一次修了 (推定)

2028年3月23日

研究の完了 (推定)

2028年3月23日

試験登録日

最初に提出

2024年4月17日

QC基準を満たした最初の提出物

2024年4月19日

最初の投稿 (実際)

2024年4月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月6日

QC基準を満たした最後の更新が送信されました

2026年11月3日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 21-1027

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The investigators will make recordings available to qualified researchers and pay attention to keep protected health information (PHI) confidential.

IPD 共有時間枠

After the complete analysis of the patient groups and after complete analysis of the healthy control group.

IPD 共有アクセス基準

To be determined.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。